Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 299 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Food Safety Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

NCT01739647
View directory record Official record
Conditions
Healthy Young Volunteers, Healthy Elderly Volunteers
Interventions
AZD3293, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

NCT02045849
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Jul 22, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Results available

Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy

NCT04148352
View directory record Official record
Conditions
Allergies Food Milk
Interventions
Dupilumab, Placebo
Drug · Other
Lead sponsor
Andrew J Long, PharmD
Other
Eligibility
4 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study and Food Effect Study for AG181

NCT06286033
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG-181, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

NCT03746067
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-134, Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Study of SBP-9330 in Healthy Subjects

NCT04948827
View directory record Official record
Conditions
Smoking Cessation
Interventions
SBP-9330, Placebo
Drug
Lead sponsor
Camino Pharma, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers

NCT04876924
View directory record Official record
Conditions
Healthy
Interventions
BBP-711, Placebo
Drug
Lead sponsor
Cantero Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 3 Interventional

Safety Study of Viaskin Peanut to Treat Peanut Allergy

NCT02916446
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250 mcg, Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 11 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
26
States / cities
Little Rock, Arkansas • Mission Viejo, California • Rolling Hills Estates, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Jul 22, 2026, 6:54 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

NCT07413666
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
ORX489 Tablets, Placebo Tablets
Drug · Other
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

NCT05043766
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF614, Naltrexone Hydrochloride, OxyContin
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease

NCT01485965
View directory record Official record
Conditions
Huntington's Disease
Interventions
SEN0014196
Drug
Lead sponsor
Siena Biotech S.p.A.
Industry
Eligibility
25 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

NCT01955109
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250 mcg
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
7 Years to 56 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

NCT05303220
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Branebrutinib, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

NCT04005807
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BPN-14967, Placebo
Drug
Lead sponsor
Belite Bio, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

NCT04603300
View directory record Official record
Conditions
Peanut Allergy
Interventions
INT301, Placebo
Drug
Lead sponsor
Intrommune Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Belleville, New Jersey • Riverdale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Not applicable Interventional

Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT02257216
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Vayarin®, Placebo
Other
Lead sponsor
Enzymotec
Industry
Eligibility
18 Years to 60 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Marietta, Georgia • Mount Kisco, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center

NCT01510626
View directory record Official record
Conditions
Immune System Diseases
Interventions
Food proteins, Omalizumab
Dietary Supplement · Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 3 Interventional

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

NCT03859700
View directory record Official record
Conditions
Peanut Allergy
Interventions
DBV712 250 mcg
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
2 Years to 5 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Standardized Eucommia Extract in the Treatment of Hypertension

NCT00626132
View directory record Official record
Conditions
Hypertension
Interventions
Eucommia
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of FTX-6058

NCT04586985
View directory record Official record
Conditions
Healthy Adult Subjects, Sickle Cell Disease
Interventions
FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses

NCT01998646
View directory record Official record
Conditions
Pharmacokinetics of ASP4058, Healthy Subjects, Food Effect of ASP4058
Interventions
ASP4058, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Miami, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 1, 2013 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants

NCT06418620
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Venglustat
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Jul 22, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers

NCT02853643
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASN002
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Jul 22, 2026, 6:54 AM EDT